{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Suzetrigine for Acute Pain Management"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Two phase 3, randomised, double-blind, placebo- and active-controlled trials"
      },
      "Participants": {
        "score": 2,
        "evidence": "conducted in adults with moderate-to-severe acute pain after abdominoplasty or bunionectomy"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised in a 2:2:1 ratio to receive suzetrigine (100 mg loading dose, then 50 mg every 12 h), hydrocodone bitartrate/acetaminophen (5/325 mg every 6 h), or placebo for 48 h"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses suzetrigine, a selective NaV1.8 inhibitor, for its efficacy and safety in treating moderate-to-severe acute pain"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the time-weighted sum of the pain intensity difference (SPID48) on the numeric pain rating scale"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using an interactive web response system"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 2,191 participants were randomised: 1,118 in the abdominoplasty trial and 1,073 in the bunionectomy trial"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "suzetrigine showing a significant reduction in pain versus placebo (abdominoplasty: mean difference 48.4, 95% CI 33.6 to 63.1, P < 0.0001; bunionectomy: mean difference 29.3, 95% CI 14.0 to 44.6, P = 0.0002)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild to moderate"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05558410, NCT05553366"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Vertex Pharmaceuticals"
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}